Programme

08:00 Registration Opens DKMS
Venue: Ballroom 4
08:30 – 08:35 | Welcome and opening remarks
Speakers: Dr Elke Neujahr and Chandré Phillipus
08:35 – 09:05
Challenges in Donor Requests: A patient Registry and Donor Centre Perspective
Speakers: Jade Worrall and Samantha Anthony
09:05 – 09:35
The importance of patient follow-ups
Speakers: Jade Worrall and Elzaan van Rooyen
09:35 – 10:35
Insights into the collection process at the DKMS Collection Centre in Germany
Speakers: Prof Utz Krug and Senait Kahsai
10:35 – 11:05
HLA and unrelated donor selection
Speaker: Dr Alexander Schmidt
11:05 – 12:30
Round table discussion: Best practices
1. Donor Requests
2. Follow-ups
3. Collection processes
Facilitators:

  1. Jade Worrall & Tshegofatso Moloke
  2. Zareen Moosa & Elzaan van Rooyen
  3. Prof Utz Krug, Senait Kahsai & Samantha Anthony

12:30
Closing
Speaker: Chandré Phillipus

09:00-10:00 SYMPOSIUM DR REDDY’S
Topic: Advancing Treatment of recurrent/metastatic Nasopharyngeal Carcinoma: Integrating Immunotherapy into Clinical Practice
Speaker: Dr. Chandrakanth M V
Venue: Committee 4
Session 1:  Joint Plenary : Diagnostics in Cancer
Chairs: Prof Georgia Demetriou & Prof  Estelle Verburgh
Venue: Ballroom 2/3
10:20-10:30 Opening
Dr Devan Moodley and Dr Justin Du Toit
10:30-11:00 Liquid biopsies in 2026
Speaker: Dr Kusha Kalideen, Lancet
11:00-11:30 Access to transplant in SA
Speaker: Ms Faith Mazibuko
MEC for Health, Gauteng Provincial Government
11:30-12:00 Risk Adapted therapy in EBC
Speaker: Dr William Audeh
Sponsored by Gknowmix
12:00-12:30 The molecular footprint of cytotoxic therapies
Speaker: Raquel Viana, Lancet
12:30-13:30 LUNCH
13:30-15:30 Session 2: Breast Track
Chair:  Dr Keo Tabane & Prof Bernardo Rapoport
Venue: Ballroom 2		 Session 2: Optimising the Recipient
Chairs: Dr Justin Du Toit & Dr Candice Hendricks
Venue: Ballroom 3
13:30-14:00 Topic: CDK 4/6 inhibitors in the therapy of hormone receptor positive, HER-2 negative metastatic breast cancer.
Speaker: Dr John Crown		 Topic: Model-based dosing of ATG for better survival after allo transplantation
Speaker: Professor Jan Jaap de Boelens
[Chief of the Paediatric Transplant and Cellular Therapy Service (TCT) at Memorial Sloane Kettering, New York, USA]
Sponsored by DKMS
14:00-14:30 Topic: ADC’s in BC. Where is it best used?
Speaker: Prof Mattea Reinisch		 Topic: Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis
Dr Donal McLornan
[University college London, UK]
Sponsored by Novartis
14:30-15:00 Topic: Multigene assays in breast cancer. What do we do in the CDK46 inhibitor era?
Speaker: Dr Mark Verrill		 Topic: Novel AML therapies
Speaker: Prof Elias Jabbour
15:00-15:30 Topic: Optimal management of the Her2 low patient
Speaker:  Prof Mattea Reinisch
Sponsored by AstraZeneca		 Topic: Haplo SCT strategies in resource limited settings
Speaker: Dr Mohan Reddy (Sankalp foundation, India)
Sponsored by: DKMS
15:30-16:00 REFRESHMENT BREAK REFRESHMENT BREAK
16:00-16:30 Topic: What’s new in Her2 amplified disease?
Speaker: Dr Mark Verril		 Topic: ‘real world’ experience of JAK inhibitors, splenomegaly management and novel agents in myelofibrosis transplant
Speaker: Dr Donal McLornan
[UCL, london]
Sponsored by Novartis
16:30-17:30 SYMPOSIUM : ASTRA ZENECA
Topic: From HER2 positive to HER2 low: Evolving treatment paradigms through real world cases
Speaker: Prof Mattea Reinisch
Venue: Committee 4 		Topic: (GRAPPA) Graft vs host disease prophylaxis in MUD allo: a RCT comparing PTCy vs ATG
Speaker: Dr Judith Schaffrath
[Martin Luther University Halle-Wittenberg, Germany]
Sponsored by DKMS
17:30-18:00 17: 45 – 18:30  SASMO AGM
Venue: Ballroom 2/3 		Topic: Update on how to treat ALL: in adolescence and young adults.
Speaker: Prof Elias Jabbour
Sponsored: Aspen Pharmacare
Topic: Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial
Speaker: Dr Judith Schaffrath
[Martin Luther University Halle-Wittenberg, Germany]
Sponsored by DKMS
18:00-18:30 SASCeTS AGM 
Venue: Ballroom 4
18:30-21:30 Exhibitors Welcome | Networking Cocktail
07:00 Registration & Exhibition Opens
07:00-07:50 SYMPOSIUM : NOVARTIS
Topic:  Optimising diagnosis and treatment in Early Breast Cancer to reduce the Risk of Recurrence
Speaker: Dr John Crown
 
Venue: Committee 4 		Meet the expert
Speaker: Professor Elias Jabbour, MD Anderson
 
Venue: Committee 5
Session 3: Joint Plenary
Chair: Prof Paul Ruff
Venue: Ballroom 2/3
08:10-08:30 Opening of Plenary
08:30-09:00 Falkson Honorary Lecture
Speaker: Professor Georgia Demetriou
09:00-09:30 A bone marrow transplant registry for South Africa
Speaker: Prof Estelle Verburgh
09:30-10:00 Fertility Lecture
Speaker: Professor Anne Partridge
5-year follow-up results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial
10:00-10:50 REFRESHMENT BREAK
10:00-10:50 SYMPOSIUM J & J
Topic: MDT without borders: Global insights in urology MDTs
Speaker: Prof Stefanie Zschabits
 
Venue: Committee 4 		 SYMPOSIUM ASTRA ZENECA
Topic: Re-evaluating HSCT in PNH: Clinical Impact of Complement Inhibition in Modern Management.
Speaker: Dr. Shreyans Gandhi, London, UK
Chair: Dr Justin Du Toit
 
Venue: Committee 5
10:50-13:00 Session 4:
SASMO
Venue: Ballroom 2		 SASCETS
Venue: Ballroom 3		 SASOPh –
PHARMACISTS
Venue: Committee 2		 NURSES
SYMPOSIUM
Venue: Ballroom 4
Session 4: Uro Genital Track
Chairs:  Dr Steven Cornish & Dr Dineo Tshabalala		 Session 4: Donor track
Chairs: Dr Sharlene Parasnath & Dr Michael Cass		 Click to view Nurses Programme
10:50-11:20 Topic: The latest developments in the treatment of metastatic Renal Cell Carcinoma.
Speaker: Prof Manuela Schmidinger
Sponsored by Acino, Part of Arcera 		Topic: Donor selection beyond HLA: focus on donor age
Speaker: Prof. Dr Tobias Holderried (Bonn, Germany) DKMS
11:20-11:50 Topic: TBC
Speaker: Prof Stefanie Zschabits		 Topic: Allo-HCT in Sickle cell disease
Speaker: Prof Julie Makani (Tanzania)
 
Sponsored by DKMS
11:50-12:20 Topic: ARPi’s in Metastatic Prostate Cancer
Speaker: tbc		 Topic: Optimising donor outcomes
Speaker: Jay Feinberg
[CEO, of Gift of Life Marrow Registry, New York]
Sponsored: SABMR
12:20-12:50 Topic: Shared Decision Making in Oncology
Speaker: Patient, Dr and Navigator
 
 
Speaker: Dr Steven Cornish
Q & A 		Topic: Launch and introduction OF FANCSA (Fanconi anaemia south Africa).
Speakers: Robin Lewis and Jolandi Lewis
Q & A
12:50-13:00 Q & A
13:00-14:00 LUNCH
13:00-13:50 SYMPOSIUM – ROCHE
Topic: Advancing Consensus in HER2+ Early Breast Cancer Treatment
Speaker: Dr Mark Verrill
 
 
Venue: Committee 4 		SYMPOSIUM J& J
Topic: Into the Future: The next Generation of Myeloma Management
Speaker: Dr. Fredrik Schjesvold
 
 
Venue: Committee 5
14:00-17:00 Session 5:
SASMO
Lung
Chairs: Dr SW Chan & Dr Tina Mathiba
Venue: Ballroom 2/3		 SASCETS
Cell & Gene Therapy SA
Chairs: Dr Perry Loebenberg & Prof Johnny Mahlangu
Venue: Ballroom 3		 SASOPh –
PHARMACISTS		 NURSES
SYMPOSIUM
Venue: Ballroom 4
14:00-14:30 Topic: The evolution of lung cancer treatment
Speaker: Dr Lizza Hendricks (Netherlands)		 Topic: CAR-NK cells (immunity Bio)
Speaker: Dr Lennie Sender & Dr Jackie Thomson		 Click to view Nurses Programme
14:30-15:00 Topic: The modern twist in small cell lung cancer
Speaker: Dr Stephanie Saw
 
Sponsored by Roche 		Topic: Access to CGT in SA
Speaker: Prof Candice Hendricks
15:00-15:30 Panel Discussion
Topic: How to improve lung cancer care in Africa		 Topic: CAR T cell trial ACTLife. 
Speaker: Dr David Brittain
15:30-16:00 REFRESHMENT BREAK
16:00-18:00 Session 6: Innovation in Oncology
Chairs: Dr Ronwyn van Eeden & Dr Mia Hugo Chairs: Dr Candice Hendricks & Dr Nandi Sigedle Click to view Nurses Programme
16:00-16:30 Topic: Immunotherapy in all skin cancer?
Speaker: Dr Teresa Amaral		 Topic: ATT progress in South Africa
Speaker: Elke Neujahr, CEO DKMS
16:30-17:00 Topic: Looking into the future – Cancer vaccines and injectables for skin cancer
Speaker:Dr Teresa Amaral		 Topic: Allo-HCT for children with inborn errors
Speaker: Prof Michael Albert, DKMS
17:00-18:00 Proffered papers
Venue: Ballroom 4 		Proffered papers
Venue: Ballroom 4
19:30-22:30 CONFERENCE DINNER
Venue: Ballroom 2/3
Session 7: Joint Plenary
Chair: Dr Yusuf Mayet
Venue: Ballroom 2/3
08:30-08:40 Plenary Intro
08:40-09:00 Topic: Essentials of setting up research units in SA?
Speaker: Prof Paul Ruff
09:00-09:30 Topic: The latest oncology trends: Real World Funder Data
Speaker: Dr Kagiso Seripe
09:30-10:00 Topic: VZV Vaccinations in Oncology patients
Speaker: Dr Jeremy Nel
10:00-11:00 REFRESHMENT BREAK
10:00-10:50 SYMPOSIUM ROCHE  

Topic: Breaking Barriers in Lung Cancer: Advanced Strategies for Managing Difficult-to-Treat Patients
Speaker: Dr Stephanie Saw

Venue: Committee 4

 SYMPOSIUM GSK
Topic: V Vaccines post-haematopoietic transplant
Speaker: Dr Jeremy Nel
11:00-12:00 SASMO
Session 8: Changes in Oncology Care
Chairs: Dr Delene Geldenhuys & Dr Richard Khanyile
Venue: Ballroom 2		 SASCeTS:
Session 8: Pre Transplant Optimisation & Post Transplant Complications
Chairs: Dr Pieter De Witt
Venue: Ballroom 3
11:00-11:30 Topic: Recent Advances and Future Directions in Nasopharyngeal Carcinoma Speaker: Dr. Chandrakanth M V Topic: Belumosudil use for chronic GVHD
Speaker: Professor Jan Jaap de Boelens [MSK, NY, USA]
Sponsored by DKMS
11:30-12:00 Topic: AI in Oncology
Speaker: Dr Hemmel Amrania		 Topic: Transfusion medicine topic
Speaker: Professor Matt Seftel (Canadian blood service)
Sponsored by: SASCeTS
12:00 Close Close

Aspen Pharmacare, the number one pharmaceutical company in South Africa is your trusted partner in healthcare.

Aspen is a global specialty and branded pharmaceutical company with more than 170 years of heritage. Our medicines reach more than 115 countries worldwide, creating access to quality healthcare for people globally.

Aspen has 24 manufacturing facilities and holds international approvals from some of the most stringent global regulatory agencies. Our manufacturing capabilities enable us to serve a broad range of therapeutic areas through multiple dosage forms, including steriles, oral doses, liquids, semi-solids, biologicals, and APIs.

Aligned with our ethos “Healthcare. We Care.”, our basket reflects a combination of legacy, innovation and reliability, positioning Aspen as a preferred and trusted partner in advancing healthcare.

Aspen’s Strategic Partnerships and growth are guided by sustainable pillars. Collaborations with global pharmaceutical companies enhance Aspen’s product portfolio and expand market reach internationally.

Aspen’s greatest strength lies in our diverse and talented teams united by our shared purpose: to improve the health and quality of life of patients around the world.

We are dedicated to enhancing patient health and quality of life while fostering trust, creating shared value and making a meaningful impact as a responsible corporation.

Aspen Pharmacare, the number one pharmaceutical company in South Africa and the largest in Africa, is your trusted partner in healthcare.

Reference 1: Based on internal analysis by Pharmacare Ltd t/a Aspen Pharmacare using data from the following source:
IQVIA South Africa Local TPM MAT FEBRUARY 2026. Brands measured in Rand value, reflecting estimates of real-world
activity. Copyright IQVIA.

Advancing Global Health Through Innovation and Impact in sub-Saharan Africa

MSD, known as Merck in the United States and Canada, leverages leading-edge science to save and improve lives globally. With over 130 years of innovation and more than 50 years in Africa, MSD expands access to medicines and vaccines while strengthening healthcare systems through partnerships, improving health outcomes across sub-Saharan Africa.

www.msdconnect.co.za/melanoma-info

AstraZeneca is a science-led, patient-focused biopharmaceutical company committed to transforming healthcare and improving outcomes for people around the world. As the burden of disease grows and populations age, we believe science, powered by digital, data and AI, is key to addressing the world’s most pressing healthcare challenges.

We strive to improve access to life-changing medicines and pioneering solutions, while also supporting earlier detection, integrated care pathways, and stronger health systems so more people can receive the right care at the right time. Powered by scientific innovation, and increasingly enabled by digital, data and AI, we are helping redefine cancer care, improve outcomes in chronic diseases, and expand access to care in a sustainable and responsible way.

Our approach is grounded in collaboration, inclusion, ethics, and sustainability, enabling us to work with partners across the healthcare ecosystem to bring forward new ideas and meaningful progress. Through science and partnership, AstraZeneca is helping shape a healthier future for patients, society, and the planet.

https://www.astrazeneca.com/country-sites/african-cluster.html

Activity ID: ZA-6886; Expiry date: 30 June 2028

Adcock Ingram is a Proudly South African company. Adcock Ingram manufactures, markets, sells and distributes a wide range of products. The diversified portfolio includes an extensive portfolio of branded and generic prescription medicines.

www.adcock.com

Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine and Eurasian countries, and Latin America.

We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing.

https://acino.swiss/

M-ZA-00002893 Expiration Date 07/03/2027

Roche Pharmaceuticals: Leading the Charge in Oncology

Roche is one of the world’s largest biotechnology company and has spent over 125 years redefining cancer care through a fusion of innovative therapies and precision medicine1.In Africa, Roche is one of the primary drivers of oncology advancements, leveraging a vast clinical trial network to deliver targeted treatments for HER2-positive breast cancer and now incorporating the lung cancer2.


Central to its regional mission is the Africa Breast Cancer Ambition, a bold initiative to rewrite the continent's survival narrative. Currently, only 5 in 10 African women survive breast cancer; Roche aims to increase this to 8 in 103 by 20404. To achieve this, Roche is committed to three critical pillars:

  • Early Detection: Increasing stage I/II diagnoses from 30% to 60%.5
  • Faster Diagnosis: Reducing the journey from symptoms to treatment to just 60 days.6
  • Treatment Access: Ensuring 80% of patients receive the standard of care.7

Through these interventions, Roche is dedicated to doing now what patients need next, pioneering an innovative pipeline to improve clinical outcomes and extend the lives of patients in South Africa.

https://www.roche.co.za/about


Roche Products (Pty) Ltd, P O Box 1469, Halfway House, 1685. Tel. +27-11-504-4746 Registration No. 1947/027044/07 Building E, Hertford Office Park, 90 Bekker Road, Vorna Valley, Midrand, 1686 Directors: R. Ferraro (Chairman) (Swiss) Dr S.D. Diale T.G. (South Africa) Renwick (British)

1 Roche South Africa. About Roche [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: About Roche ZA

2 Roche. A new era of healthcare in Africa with AMA [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: A new era of healthcare in Africa with AMA

3 Roche. African Breast Cancer Ambition (ABCA) [Internet; cited 2026 Mar 2]. Available from: Africa Breast Cancer Ambition

4 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

5 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

6 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

7 Roche Africa. Working together to help more women in Africa survive breast cancer [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: Working together to help more women in Africa survive breast cancer